WuXi Biologics

Haier Biomedical has released its 2026 interim report. First-half operating revenue reached a record high of 1.296 billion yuan, up 8.45 percent year on year, while net profit attributable to the parent company was 147 million yuan, up 3.28 percent. Both revenue and profit growth in the second quarter were faster than in the first quarter. Pharmaceutical customers were the main driver of revenue growth, with related revenue up 23 percent in the first half. Domestically, the company deepened cooperation with leading pharmaceutical firms including WuXi Biologics, GenSci, Pien Tze Huang and Qilu Pharmaceutical. Overseas, it newly entered research and production bases in countries such as the United Kingdom and Singapore, and has now served nearly half of the world's top 25 pharmaceutical companies. Growth continued in major global markets, with the European Union, the United Kingdom and the United States together rising 17 percent. Smart medication solutions expanded rapidly into 10 countries including Thailand, Vietnam, Malaysia, Morocco and Saudi Arabia. The low-temperature business grew 13 percent year on year, achieving positive growth for four consecutive quarters. The laboratory solutions business grew 19 percent, and the smart medication business grew 11 percent. Revenue from AI-related businesses rose to 18 percent of total revenue, up 3 percentage points from 2025. The company expects both revenue and profit growth to accelerate in the second half, with full-year profit growth broadly matching revenue growth.

Apeloa Pharmaceutical's holding subsidiary Anteyutai has signed a five-year Strategic Cooperation Framework Agreement with WuXi Biologics and Duoning Biotech. The three parties will jointly promote the development of Anteyutai's large-molecule drug pipeline, industrialization capacity building, and supply chain system improvement. Under the agreement, WuXi Biologics will provide Anteyutai with full-process R&D and manufacturing services for biologics, commercial production and supply assurance, commercial production workshop construction and GMP empowerment, and may explore capital cooperation such as equity investment. Duoning Biotech, as a strategic supplier, will provide core consumables including culture media, filter membranes, and chromatography resins, along with supporting hardware solutions, to help achieve process synergy, cost reduction, and supply chain stability.

The products managed by two star fund managers at Ruiyuan Fund, Fu Pengbo and Zhao Feng, have disclosed their second-quarter 2026 reports, revealing their latest top ten heavy-weight holdings. The Ruiyuan Growth Value Hybrid Fund, managed by Fu Pengbo and Zhu Lin, initiated a position in Focuslight Technologies for the first time with 4.5277 million shares, while significantly reducing holdings in Zhongji Innolight and Dongshan Precision. Its Hong Kong stock allocation dropped to a historic low of 3.35%. The Ruiyuan Balanced Value Three-Year Holding Fund, managed by Zhao Feng, bought back into WuXi Biologics after a one-year hiatus, with a position of 9.4275 million shares, and increased holdings in ZTO Express and China Resources Land. At the end of the second quarter, the Ruiyuan Growth Value Hybrid Fund had a net asset value of 22.201 billion yuan, an increase of 4.045 billion yuan from the end of the first quarter, with the Class A share net value growth rate at 45.79%. In their quarterly reports, the two fund managers stated that the portfolio added targets in high-power semiconductor lasers and micro-nano optical solutions, reduced holdings in internet technology companies, and believe that the high returns implied by excessively low valuations are certain.

The Sci-Tech Innovation Medical ETF Huaxia has reached a latest size of 249 million yuan, a nearly one-year high. The ETF has seen net inflows for 11 consecutive days, attracting a total of 139 million yuan, with an average daily net inflow of 12.6 million yuan. Huayuan Securities believes that after a decade of innovation and transformation, innovative drugs have significantly opened a new growth curve for Chinese pharmaceutical companies. The industry has reached a considerable scale, the trend of going overseas continues, while domestic aging demand and the improvement of the medical insurance payment system continue to drive incremental growth. The Hang Seng Medical ETF Huaxia closely tracks the Hang Seng Biotechnology Index, with the top ten holdings including Innovent Biologics, BeiGene, WuXi Biologics, and others, accounting for a combined 71.34%.

WuXi Biologics has received GMP certification from Brazil's ANVISA for two manufacturing facilities and a packaging center in Wuxi, enabling end-to-end commercial production of an anti-PD-L1 monoclonal antibody for cancer immunotherapy. The five-day inspection of Drug Substance Facility 2, Drug Product Facility 1, and the Drug Product Packaging Center concluded with zero findings. The certification allows WuXi Biologics to provide integrated drug substance and drug product manufacturing for global commercial supply, including entry into Latin America. The company has now passed 46 regulatory inspections and holds a 100% pass rate for FDA Pre-License Inspections.

WuXi Biologics announced that its MFG17 drug substance facility in Shanghai has successfully completed its first GMP production campaign with zero deviations and stable critical process parameters. MFG17 is the 25th drug substance facility in the company's global network and is equipped with multiple single-use bioreactors providing a total capacity of 9,000 liters for 80 to 100 batches annually. The facility supports various process modes including fed-batch, perfusion, and fully automated continuous manufacturing, and is advancing a digitalization strategy to enhance operational efficiency. CEO Dr. Chris Chen stated that the achievement strengthens the company's manufacturing capabilities and supports global partners in accelerating delivery of innovative biologics.

WuXi Biologics' Biosafety Testing Center in Suzhou has received its fourth Good Manufacturing Practice certification from the European Medicines Agency, enabling 19 biologics from 13 clients to pursue European Union marketing authorization. The four-day inspection, which concluded with zero critical findings, covered quality management, facilities, testing methods, standard operating procedures, computerized systems, and personnel. The 19 products span antibodies, enzymes, and fusion proteins, with the majority developed and manufactured on WuXi Biologics' integrated platform. The facility's quality system, infrastructure, technical capabilities, data integrity, and organizational management were highly recognized by the EMA. As of December 2025, the company's biosafety testing centers in Suzhou and Shanghai have supported over 1,700 investigational new drug or biologics license applications.